Skip to main content
. 2018 Nov 13;35(4):217–228. doi: 10.4274/tjh.2018.0196

Table 5. Clinical trials targeting disialoganglioside 2, human epidermal growth factor receptor 2, and epidermal growth factor receptor variant III.

graphic file with name TJH-35-217-g6.jpg